BioCentury
ARTICLE | Product Development

SMA data validate growth factor-targeting platform for Scholar Rock as stock price doubles

Phase II data breathes new life into theory that blocking myostatin can improve muscle growth, function

October 27, 2020 11:53 PM UTC

Scholar Rock’s interim Phase II data for SRK-015 in spinal muscular atrophy is breathing new life into the theory that blocking myostatin can improve muscle growth and function. It also provides validation for the company’s platform for tackling challenging growth factor drug targets by blocking their latent forms.

Scholar Rock Holding Corp. (NASDAQ:SRRK) saw its share price more than double on Tuesday following the announcement that its lead candidate, SRK-015, improved motor function at six months in Type 2 and Type 3 SMA patients across all three cohorts of the Phase II TOPOZ study. ...

BCIQ Company Profiles

Scholar Rock Holding Corp.

BCIQ Target Profiles

Myostatin (MSTN) (GDF8)